Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00730483 Active, not recruiting - Metastatic Cancer Clinical Trials

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

Start date: February 2009
Phase: N/A
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Infusing doxorubicin beads into the liver, and blocking blood flow to the tumor, may keep doxorubicin near the tumor and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects of doxorubicin beads and to see how well they work in treating patients with unresectable liver metastases from neuroendocrine tumors.

NCT ID: NCT00730379 Completed - Neoplasms Clinical Trials

A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Start date: July 2008
Phase: Phase 1
Study type: Interventional

This study is being done to find the best tolerated dose of ridaforolimus and dalotuzumab in patients who have advanced cancer and to observe any anti-tumor activity in these patients.

NCT ID: NCT00728871 Recruiting - Cervical Cancer Clinical Trials

The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis

Start date: December 2005
Phase: N/A
Study type: Interventional

A. To investigate the relationship between serum titer of anti-HPV16 antibody and clinicopathological factors of cervical cancer patients. B. To investigate that if the serum titer of anti-HPV16 antibody could be a prognostic factor in the cervical cancer patients. C. To investigate the serum titer of anti-HPV16 antibody in HPV16-infected populations with various disease status such as infection only, precancerous lesion, and early and advanced cervical cancer.

NCT ID: NCT00728585 Withdrawn - Malignant Neoplasm Clinical Trials

Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant

Start date: March 13, 2008
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying palifermin to see how well it works compared with a placebo in preventing oral mucositis caused by chemotherapy and/or radiation therapy in young patients undergoing stem cell transplant. Palifermin may help relieve or prevent oral mucositis caused by chemotherapy and radiation therapy in young patients undergoing stem cell transplant.

NCT ID: NCT00728468 Completed - Clinical trials for Advanced Malignant Solid Tumors

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Start date: September 2008
Phase: Phase 1
Study type: Interventional

Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan. The purpose of this study is to test the impact of PF-00299804 on the activity of CYP2D6, and how the human body handles dextromethorphan.

NCT ID: NCT00726830 Terminated - Pain Clinical Trials

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Start date: March 2009
Phase: N/A
Study type: Interventional

RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer. PURPOSE: This randomized clinical trial is studying methadone to see how well it works compared with morphine or oxycodone in treating pain in patients with cancer.

NCT ID: NCT00726752 Completed - Neoplasms Clinical Trials

A Study In Patients With Advanced Solid Tumor

Start date: July 2008
Phase: Phase 1
Study type: Interventional

This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses

NCT ID: NCT00725634 Completed - Multiple Myeloma Clinical Trials

A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma

P05538
Start date: September 2008
Phase: Phase 1
Study type: Interventional

Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed or refractory solid tumors, lymphoma, or multiple myeloma. The study will also determine the safety, tolerability and DLTs of AV-299 in combination with erlotinib in patients with relapsed or refractory solid tumors.

NCT ID: NCT00725387 Completed - Neoplasms Clinical Trials

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Start date: August 2007
Phase:
Study type: Observational

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

NCT ID: NCT00724425 Terminated - Clinical trials for Advanced Malignancies

A Phase 1 Dose Escalation Study of IPI-493

Start date: July 2008
Phase: Phase 1
Study type: Interventional

IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.